Business Wire

PMC Group and The Chakrabarti Foundation Make Donation to Ramakrishna Mission Saradapitha Belur Math of West Bengal

14.3.2023 12:45:00 EET | Business Wire | Press release

Share

Paritosh M. Chakrabarti, business owner, author and philanthropist, today announced PMC Group and The Chakrabarti Foundation have made a sizeable donation of land and property to the Ramakrishna Mission Saradapitha Belur Math of West Bengal.

“Contributing to the Ramakrishna Mission Saradapitha is an honor. The Mission enshrines the teachings of India’s greatest spiritual leader and unifier of humanity, Swami Vivekananda,” explained Paritosh Chakrabarti. “This gift is a way for me to further those ideals. I am appreciative to Belur Math for accepting the donation. These gifts are also part of the ‘soul’ of PMC Group that I describe in my upcoming book, The Makings of PMC Group – A Corporation with a Soul."

The donation includes the notable Bose House which has been witness to many historical events and carries memories of great patriots and revolutionaries, the surrounding land, and a significant financial gift. The financial gift will provide for 1.) construction and development of two museum rooms, each housing panel exhibition-cum-photo galleries, manuscripts, rare and valuable collections and potentially, a multimedia presentation depicting the lives, activities, and legacies of Swami Vivekananda and Netaji Subhas Chandra Bose, 2.) production of cultural and educational activities to promote inter-cultural and inter-religious harmony and, 3.) installation of a commemorative plaque stating: “This historic Bose House Property has been donated by Paritosh M. Chakrabarti and Srimati Chakrabarti to Ramakrishna Mission Saradapitha, Belur Math for the Construction and Development of a Cultural and Educational Center to Promote the legacy of Swamiji and Netaji”.

The chairman of Rishra Municipality, Vijay Sagar Mishra said, “It’s a matter of great joy and honor for all of us to watch the handing over ceremony of Rishra Bose House to Ramakrishna Mission Saradapitha Belur Math. Converting it to a museum will bring the common people closer to the works and activities of the great patriot Netaji Subhas Chandra Bose and Swami Vivekananda. The present generation must be made aware of the glorious history so that they can take lessons from it and go ahead in serving the motherland.”

ABOUT PMC
PMC Group, owned by Paritosh M. Chakrabarti and his family, is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.

ABOUT THE CHAKRABARTI FOUNDATION
The Chakrabarti Foundation is a non-profit organization dedicated to promoting education around the world and believes excellence in education is a primary requirement for enduring civilization. To learn more please visit https://pmc-group.com/chakrabarti-foundation.

ABOUT RAMAKRISHNA MISSION SARADAPITHA BELUR MATH
Ramakrishna Mission Saradapitha Belur Math is a well-known and reputed philanthropic organization serving the society of India and abroad irrespective of caste, color, creed, religion, nationality, gender, regional bias, etc., through its vast network of nearly more than 250 branch-centers in the fields of education, culture, religion, health, relief and rehabilitation, rural and tribal development, publications, teachings and preaching and a large number of allied areas all of which are for the all-around development of the individual and the society as a whole. More can be found at https://belurmath.org/ramakrishna-mission-saradapitha-belur.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patti Griggs 856-533-1870
pgriggs@pmc-group.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye